BioCentury | Jan 6, 2017
Company News

CymaBay, Kowa deal

...CymaBay granted the Kowa Pharmaceuticals America Inc. subsidiary of Kowa rights in the U.S. to arhalofenate...
...royalties. Kowa will be responsible for development and commercialization. CymaBay will retain all rights to arhalofenate...
...terms. CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Kowa Co. Ltd. , Nagoya, Japan Business: Endocrine/Metabolic Chris Lieu arhalofenate CymaBay...
BioCentury | Jan 4, 2017
Company News

CymaBay grants Kowa U.S. rights to gout candidate

...Inc. subsidiary of Kowa Co. Ltd. (Nagoya, Japan) rights in the U.S. to arhalofenate ( MBX-102...
...CymaBay will retain all rights to arhalofenate outside the U.S. In February 2015, CymaBay said arhalofenate...
...Extra, Feb. 24, 2015) . CymaBay gained $0.17 (10%) to $1.90 during market hours Tuesday. Becky Simon arhalofenate CymaBay...
BioCentury | Mar 2, 2015
Clinical News

Arhalofenate: Phase IIb data

...history of >=3 flares in the last 12 months showed that 800 mg once-daily oral arhalofenate...
...at week 12 vs. 300 mg once-daily allopurinol (0.66 vs. 1.24, p=0.0056). Additionally, 800 mg arhalofenate...
...start Phase III testing of arhalofenate. CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate ( MBX-102...
BioCentury | Feb 25, 2015
Clinical News

CymaBay falls on Phase IIb gout data

...$9.98 on Tuesday after reporting interim data from its Phase IIb trial of arhalofenate ( MBX-102...
...12 weeks (p=0.0056) -- CymaBay said neither a 600 mg nor 800 mg dose of arhalofenate...
...another Phase II trial in which 100% of gout patients receiving 800 mg of oral arhalofenate...
BioCentury | Feb 2, 2015
Clinical News

Arhalofenate: Preliminary Phase II data

...gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate...
...febuxostat and 20%, 93% (p<0.001) and 100% (p<0.01) of patients receiving once-daily 800 mg oral arhalofenate...
...also received colchicine for flare prophylaxis. CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate ( MBX-102...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

...to watch in 2015. The biotech expects to report Phase IIb data for arhalofenate ( MBX-102...
BioCentury | Oct 6, 2014
Clinical News

Arhalofenate: Completed Phase IIb enrollment

...patients in a double-blind, placebo-controlled, international Phase IIb trial comparing 600 and 800 mg oral arhalofenate...
...a review of interim safety data. CymaBay Therapeutics Inc. (NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate ( MBX-102...
...SLC22A12) (URAT1) Description: Uricosuric agent Indication: Treat gout Endpoint: Flare incidence rate for 800 mg arhalofenate...
BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

...the company proposed to raise up to $30 million in the offering. CymaBay's arhalofenate ( MBX-102...
BioCentury | Jul 23, 2014
Financial News

CymaBay raises $22 million in follow-on

...a follow-on underwritten by Cowen; Stifel; Roth Capital Partners; and National Securities. CymaBay's arhalofenate ( MBX-102...
BioCentury | Jul 21, 2014
Finance

Highlights of weekly biotech stock moves

...the Form 10 pathway in October and began trading on the OTCQB in January. CymaBay's arhalofenate...
Items per page:
1 - 10 of 55